Clinical Trial: RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891871) titled 'RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab' on Oct. 08.

Brief Summary: Elranatamab is an effective BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma (RRMM). However, implementation in routine practice remains challenging due to monitoring requirements during step-up dosing for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), together with the long-term burden of infection prevention and immunoglobulin replacement. Delivery models across the NHS vary considerably, including inpatient, ambulatory, outpatient, and vi...